Related Experiment Video

Updated: Jun 23, 2026

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

Platelet cytosolic calcium, peripheral hemodynamics, and vasodilatory peptides in liver cirrhosis

F Rodríguez-Pérez1, C M Isales, R J Groszmann

  • 1Section of Digestive Diseases, West Haven Veterans Affairs Medical Center, Yale University School of Medicine, Connecticut.

Gastroenterology
|September 1, 1993
PubMed

Insights

Cirrhotic patients exhibit significantly lower platelet calcium levels, which correlate with altered blood pressure and blood flow. This suggests platelets may help understand vasodilation in chronic liver disease.

Area of Science:

  • Cardiovascular Physiology
  • Hepatology
  • Hematology

Background:

  • Platelet cytosolic calcium concentration ([Ca2+]i) is a potential indicator of vascular smooth muscle cell changes.
  • Investigating platelet [Ca2+]i in cirrhosis is crucial for understanding associated hemodynamic alterations.

Purpose of the Study:

  • To determine if platelet [Ca2+]i is altered in patients with cirrhosis.
  • To examine the relationship between platelet [Ca2+]i, peripheral hemodynamics, and specific peptide levels in cirrhosis.

Main Methods:

  • Compared platelet [Ca2+]i, glucagon, substance P (SP), and vasoactive intestinal peptide (VIP) levels in 14 cirrhotic patients and 11 healthy controls.
  • Measured mean arterial pressure (MAP), forearm blood flow (FBF), and calculated forearm vascular resistance (FVR).

Main Results:

  • Cirrhotic patients showed significantly lower platelet [Ca2+]i (50.1 vs. 73.0 nmol/L) and higher glucagon levels.
  • MAP and FVR were significantly reduced in cirrhotic patients compared to controls.
  • Platelet [Ca2+]i strongly correlated with MAP (r=0.81), FVR (r=0.87), and diastolic blood pressure (r=0.78) in cirrhotic patients.

Conclusions:

  • Cirrhosis is associated with a marked reduction in platelet [Ca2+]i.
  • The decreased platelet [Ca2+]i in cirrhosis is linked to peripheral hemodynamic changes.
  • Platelets may serve as a valuable biomarker for studying vasodilation mechanisms in chronic liver disease.
Abstract

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Imaging Ca2+ Signals in Small Pulmonary Veins at Physiological Intraluminal Pressures05:35

Imaging Ca2+ Signals in Small Pulmonary Veins at Physiological Intraluminal Pressures

Published on: March 21, 2025

Related Concept Videos

Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...